Caseware UK (AP4) 2023.0.135 2023.0.135 2023-12-312023-12-310No description of principal activity2023-04-27false1truetruefalse 14830991 2023-04-26 14830991 2023-04-27 2023-12-31 14830991 2022-04-27 2023-04-26 14830991 2023-12-31 14830991 1 2023-04-27 2023-12-31 14830991 d:Director1 2023-04-27 2023-12-31 14830991 d:Director2 2023-04-27 2023-12-31 14830991 d:RegisteredOffice 2023-04-27 2023-12-31 14830991 c:CurrentFinancialInstruments 2023-12-31 14830991 c:CurrentFinancialInstruments c:WithinOneYear 2023-12-31 14830991 c:ShareCapital 2023-12-31 14830991 c:RetainedEarningsAccumulatedLosses 2023-12-31 14830991 d:FRS102 2023-04-27 2023-12-31 14830991 d:Audited 2023-04-27 2023-12-31 14830991 d:FullAccounts 2023-04-27 2023-12-31 14830991 d:PrivateLimitedCompanyLtd 2023-04-27 2023-12-31 14830991 d:SmallCompaniesRegimeForAccounts 2023-04-27 2023-12-31 14830991 e:PoundSterling 2023-04-27 2023-12-31 iso4217:GBP xbrli:pure
Registered number: 14830991 (England and Wales)














MF CLINICAL LIMITED

DIRECTORS' REPORT AND FINANCIAL STATEMENTS

FOR THE PERIOD ENDED 31 DECEMBER 2023

 
MF CLINICAL LIMITED
 
 
COMPANY INFORMATION


Directors
K Thoelke 
J Trepanier 




Registered number
14830991



Registered office
Birchin Court
5th Floor

19-25 Birchin Lane

London

United Kingdom

EC3V 9DU




Independent auditors
ZEDRA Corporate Reporting Services (UK) Limited





 
MF CLINICAL LIMITED
 

CONTENTS



Page
Balance Sheet
 
1
Notes to the Financial Statements
 
2 - 3


 
MF CLINICAL LIMITED
REGISTERED NUMBER:14830991

BALANCE SHEET
AS AT 31 DECEMBER 2023

2023
Note
£

  

Current assets
  

Debtors: amounts falling due within one year
 4 
816

  
816

Creditors: amounts falling due within one year
 5 
(136,165)

Net current liabilities
  
 
 
(135,349)

Total assets less current liabilities
  
(135,349)

  

Net liabilities
  
(135,349)


Capital and reserves
  

Called up share capital 
  
1

Profit and loss account
  
(135,350)

  
(135,349)


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 


J Trepanier
Director

Date: 20 December 2024

The notes on pages 2 to 3 form part of these financial statements.

Page 1

 
MF CLINICAL LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

1.Accounting policies

 
1.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view. 
The Company’s functional and presentational currency is GBP (£), as that is the primary currency in which the Company transacts.

The following principal accounting policies have been applied:

 
1.2

Going concern

The purpose of the Company is to support the parent Paradigm Health, Inc. with its global employee tax obligations. The Company is reliant on the continued support of the parent company in order to remain a going concern.
The Company has received written confirmation from its parent company that it will continue to provide financial support to the Company for a period of at least 12 months from the date of signing these financial statements. Furthermore, the directors have assessed the ability of the parent company to provide this support based upon their cashflow forecasts and have concluded that the parent will have sufficient working capital to provide necessary support. For these reasons, the directors continue to adopt the going concern basis in preparing these financial statements.

 
1.3

Debtors

Short-term debtors are measured at transaction price, less any impairment.

 
1.4

Creditors

Short term creditors are measured at the transaction price. Amounts owed to group undertakings are intercompany loans measured at cost. These loans are unsecured, interest free and repayable on demand.


2.


Auditors' information

The auditors' report on the financial statements for the period ended 31 December 2023 was unqualified.

The audit report was signed on 27 December 2024 by Edward Wallis ACA (Senior Statutory Auditor) on behalf of ZEDRA Corporate Reporting Services (UK) Limited.


3.


Employees

The average monthly number of employees during the period was 1.
 

Page 2

 
MF CLINICAL LIMITED
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2023

4.


Debtors

2023
£


Prepayments and accrued income
816

816



5.


Creditors: Amounts falling due within one year

2023
£

Amounts owed to group undertakings
116,051

Accruals and deferred income
20,114

136,165



6.


Controlling party

Paradigm, Inc. is the parent company of the smallest group for which consolidated financial statements are drawn up of which the Company is a member. The registered office of the parent company is: 175 S. 3rd Street, Suite 1000, Columbus, OH 43215-5197, United States.


7.


Post balance sheet events

There were no adjusting or non-adjusting events occurring between the end of the reporting period and the date of these financial statements were approved.

 
Page 3